Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ricolinostat + SJB3-019A |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ricolinostat | ACY-1215 | HDAC Inhibitor 45 | Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524, PMID: 32705192). | |
SJB3-019A | USP1 inhibitor 7 | SJB3-019A irreversibly inhibits USP1, resulting in decreased USP1 deubiquitinylating activity and downstream DNA repair pathway signaling, and reduced tumor cell viability (PMID: 28270494). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|